Hyperforat

St. John's Wort Dry Extract, the active ingredient in Hyperforat, is a herbal antidepressant presented as an oral herbal extract for oral use. Extracted with 60 % ethanol, it is marketed in the EU and is intended to support mood in individuals experiencing mild to moderate depression and seasonal affective disorder.

GNH USA supplies Hyperforat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality, regulatory compliance and reliable logistics for this herbal antidepressant across global markets.

Hyperforat, a herbal antidepressant, is used to address mood disorders related to neurotransmitter imbalances.

Mild to moderate depression: helps improve mood and reduce depressive symptoms. Seasonal affective disorder: alleviates low mood associated with seasonal changes. Adjustment-related low mood: supports emotional balance during stressful life adjustments.

St. John's Wort Dry Extract may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal discomfort - Dizziness - Headache - Fatigue - Skin photosensitivity - Dry mouth

Serious or Rare Side Effects: - Serotonin syndrome when combined with serotonergic drugs - Severe allergic reactions, including anaphylaxis - Hyponatremia - Elevation of liver enzymes - Psychotic episodes - Cardiac arrhythmias

When using Hyperforat, consider the following precautions: - Assess psychiatric history: ensure appropriate indication before initiating therapy. - Monitor for drug interactions: review concomitant medications for serotonergic activity. - Avoid use in pregnancy unless advised: safety data are insufficient. - Caution in breastfeeding: potential transfer to infant via milk. - Discontinue before surgery: risk of increased bleeding. - Protect from sunlight: photosensitivity may occur. - Store at ambient temperature: keep in original packaging, protect from moisture.

Hyperforat can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin toxicity. - Tricyclic antidepressants: increased plasma concentrations. - Anticoagulants (e.g., warfarin): enhanced bleeding risk. - Oral contraceptives: reduced hormonal efficacy.

Moderate Interactions (Monitor Closely): - Antiepileptics (phenytoin, carbamazepine): decreased drug levels. - Immunosuppressants (cyclosporine, tacrolimus): reduced effectiveness. - Digoxin: lowered serum concentrations. - HIV protease inhibitors: diminished antiviral activity. - Other CYP3A4 substrates: possible altered metabolism.